GSK to boost respiratory portfolio with $1.4 bln Aiolos Bio deal
British drugmaker GSK on Tuesday said it would acquire Aiolos Bio for a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments. The...
Stay updated with breaking news from Eva Mathews. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
British drugmaker GSK on Tuesday said it would acquire Aiolos Bio for a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments. The...
Founded in 2023, Aiolos is focused on developing therapies for respiratory and inflammatory conditions. It is currently developing 'AIO-001', a treatment for asthma which is ready to enter mid-stage clinical trials. The drug would expand the reach of its current respiratory biologics portfolio, including to the 40% of severe asthma patients with certain conditions, where treatment options are still needed, said Tony Wood, GSK's chief scientific officer.
Online trading platform CMC Markets raised its full-year operating income forecast on Monday, citing a strong third quarter on the back of an improvement in market conditions. The group...
Shell on Monday flagged impairment charges of about $2.5 billion to $4.5 billion for the fourth quarter, mainly related to the Singapore refining and chemicals hub the oil major is looking to...
Shell on Monday flagged impairment charges of about $2.5 billion to $4.5 billion for the fourth quarter, mainly related to the Singapore refining and chemicals hub the oil major is looking to sell. ...